Physician profile
John M Surso
NPI 1003887902
$4,057.82
in general payments reported to CMS, 2019-2025
28 companies · $161 in 2025
The $161 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,966 · 2020: $234 · 2021: $49.55 · 2022: $62.60 · 2023: $434 · 2024: $150 · 2025: $161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $745.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $744.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $960.65 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $616.68 | 2019-2025 | Breztri, Farxiga |
| Abbvie INC. | $428.07 | 2019-2024 | Ubrelvy, Qulipta |
| Astellas Pharma US INC | $272.28 | 2019-2023 | Veozah |
| Pfizer INC. | $178.27 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $160.69 | 2019 | |
| Lilly USA, LLC | $158.45 | 2019-2023 | Mounjaro |
| Janssen Pharmaceuticals, INC | $152.78 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $148.97 | 2019 | |
| Glaxosmithkline, LLC. | $141.98 | 2019-2020 | |
| Novo Nordisk INC | $108.02 | 2019 | |
| Novartis Pharmaceuticals Corporation | $104.21 | 2019-2020 | |
| Penumbra, INC. | $98.88 | 2023 | Penumbra System |
| Takeda Pharmaceuticals U.S.A., INC. | $85.37 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.84 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $65.02 | 2019 | |
| Allergan, INC. | $63.82 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $40.88 | 2024-2025 | Voquezna |
| Ironshore Pharmaceuticals INC. | $32.87 | 2019 | |
| Hikma Pharmaceuticals USA | $28.42 | 2019 | |
| Abbott Laboratories | $24.87 | 2021 | |
| Ethicon US, LLC | $22.02 | 2025 | Echelon; Endopath |
| Sanofi Pasteur INC. | $17.99 | 2019 | |
| Shire North American Group INC | $17.60 | 2019 | |
| Medtronic, INC. | $16.85 | 2021 | |
| Portola Pharmaceuticals, LLC | $15.70 | 2020 | |
| Sanofi-Aventis U.S. LLC | $13.81 | 2019 | |
| Clarus Therapeutics INC. | $7.83 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Surso listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.